Switch theme
Sign up to access all valuation multiples
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’.
2014
285
LTM Revenue $65.3M
Last FY EBITDA -$51.6M
$51.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prenetics Global has a last 12-month revenue (LTM) of $65.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prenetics Global achieved revenue of $30.6M and an EBITDA of -$51.6M.
Prenetics Global expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prenetics Global valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $65.3M | XXX | $30.6M | XXX | XXX | XXX |
| Gross Profit | $32.3M | XXX | $15.4M | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$51.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -168% | XXX | XXX | XXX |
| EBIT | -$39.6M | XXX | -$50.9M | XXX | XXX | XXX |
| EBIT Margin | -61% | XXX | -166% | XXX | XXX | XXX |
| Net Profit | -$40.8M | XXX | -$46.3M | XXX | XXX | XXX |
| Net Margin | -62% | XXX | -151% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Prenetics Global's stock price is $8.
Prenetics Global has current market cap of $105M, and EV of $51.5M.
See Prenetics Global trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51.5M | $105M | XXX | XXX | XXX | XXX | $-3.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Prenetics Global has market cap of $105M and EV of $51.5M.
Prenetics Global's trades at 1.7x EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Prenetics Global's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prenetics Global has a P/E ratio of -2.6x.
See valuation multiples for Prenetics Global and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $105M | XXX | $105M | XXX | XXX | XXX |
| EV (current) | $51.5M | XXX | $51.5M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -1.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.6x | XXX | -2.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrenetics Global's last 12 month revenue growth is 86%
Prenetics Global's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Prenetics Global's rule of 40 is -138% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prenetics Global's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prenetics Global and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 86% | XXX | 117% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -168% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -138% | XXX | -82% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 216% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prenetics Global acquired XXX companies to date.
Last acquisition by Prenetics Global was XXXXXXXX, XXXXX XXXXX XXXXXX . Prenetics Global acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prenetics Global founded? | Prenetics Global was founded in 2014. |
| Where is Prenetics Global headquartered? | Prenetics Global is headquartered in United States of America. |
| How many employees does Prenetics Global have? | As of today, Prenetics Global has 285 employees. |
| Who is the CEO of Prenetics Global? | Prenetics Global's CEO is Mr. Sheng Wu Danny Yeung. |
| Is Prenetics Global publicy listed? | Yes, Prenetics Global is a public company listed on NAS. |
| What is the stock symbol of Prenetics Global? | Prenetics Global trades under PRE ticker. |
| When did Prenetics Global go public? | Prenetics Global went public in 2022. |
| Who are competitors of Prenetics Global? | Similar companies to Prenetics Global include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Prenetics Global? | Prenetics Global's current market cap is $105M |
| What is the current revenue of Prenetics Global? | Prenetics Global's last 12 months revenue is $65.3M. |
| What is the current revenue growth of Prenetics Global? | Prenetics Global revenue growth (NTM/LTM) is 86%. |
| What is the current EV/Revenue multiple of Prenetics Global? | Current revenue multiple of Prenetics Global is 0.8x. |
| Is Prenetics Global profitable? | Yes, Prenetics Global is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
